EP0989860A4 - METHODS AND COMPOSITIONS FOR INACTIVATING INFECTIOUS AGENTS USING LACTOFERRIN AND RELATED MOLECULES - Google Patents

METHODS AND COMPOSITIONS FOR INACTIVATING INFECTIOUS AGENTS USING LACTOFERRIN AND RELATED MOLECULES

Info

Publication number
EP0989860A4
EP0989860A4 EP99917408A EP99917408A EP0989860A4 EP 0989860 A4 EP0989860 A4 EP 0989860A4 EP 99917408 A EP99917408 A EP 99917408A EP 99917408 A EP99917408 A EP 99917408A EP 0989860 A4 EP0989860 A4 EP 0989860A4
Authority
EP
European Patent Office
Prior art keywords
lactoferrin
compositions
methods
infectious agents
related molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99917408A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0989860A1 (en
Inventor
Andrew G Plaut
Jiazhou Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Medical Center Hospitals Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Publication of EP0989860A1 publication Critical patent/EP0989860A1/en
Publication of EP0989860A4 publication Critical patent/EP0989860A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP99917408A 1998-04-13 1999-04-12 METHODS AND COMPOSITIONS FOR INACTIVATING INFECTIOUS AGENTS USING LACTOFERRIN AND RELATED MOLECULES Withdrawn EP0989860A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8156498P 1998-04-13 1998-04-13
US81564P 1998-04-13
PCT/US1999/007931 WO1999052545A1 (en) 1998-04-13 1999-04-12 Methods and compositions for inactivating infectious agents using lactoferrin and related molecules

Publications (2)

Publication Number Publication Date
EP0989860A1 EP0989860A1 (en) 2000-04-05
EP0989860A4 true EP0989860A4 (en) 2000-07-19

Family

ID=22164962

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99917408A Withdrawn EP0989860A4 (en) 1998-04-13 1999-04-12 METHODS AND COMPOSITIONS FOR INACTIVATING INFECTIOUS AGENTS USING LACTOFERRIN AND RELATED MOLECULES

Country Status (5)

Country Link
EP (1) EP0989860A4 (ja)
JP (1) JP2002508009A (ja)
AU (1) AU3554099A (ja)
CA (1) CA2294018A1 (ja)
WO (1) WO1999052545A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635766A4 (en) * 2003-06-06 2009-09-30 Agennix Inc LACTOFERRIN AS ADJUVANS IN CANCER VACCINES
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
ITRM20080163A1 (it) * 2008-03-26 2009-09-27 Maurizio Acri Uso della lattoferrina per la prevenzione delle sepsi neonatali in neonati prematuri
CN107586334B (zh) * 2017-08-29 2020-06-23 杭州医学院 一种治疗流感嗜血杆菌感染的血清的制备方法及该血清的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220130A (ja) * 1990-01-25 1991-09-27 Snow Brand Milk Prod Co Ltd 病原菌付着阻止剤及びそれを含有する飲食品等
US5304633A (en) * 1990-09-07 1994-04-19 Morinaga Milk Industry Co., Ltd. Fragments of lactoferrin having potent antimicrobial activity
WO1997005884A1 (en) * 1995-08-07 1997-02-20 New England Medical Center Hospitals, Inc. Infant formula and infant formula additives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
US5861491A (en) * 1994-02-16 1999-01-19 Pharming B.V. Isolation of lactoferrin from milk
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220130A (ja) * 1990-01-25 1991-09-27 Snow Brand Milk Prod Co Ltd 病原菌付着阻止剤及びそれを含有する飲食品等
US5304633A (en) * 1990-09-07 1994-04-19 Morinaga Milk Industry Co., Ltd. Fragments of lactoferrin having potent antimicrobial activity
WO1997005884A1 (en) * 1995-08-07 1997-02-20 New England Medical Center Hospitals, Inc. Infant formula and infant formula additives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199145, Derwent World Patents Index; Class B04, AN 1991-329196, XP002138451 *
LEGRAND, D., ET AL.: "Evidence for interactions between the 30kDa N- and 50kDa C-terminal tryptic fragments of human lactotransferrin", BIOCHEM. J., vol. 236, 1986, pages 839 - 844, XP002921478 *
QUI, J., ET AL.: "Human milk lactoferrin extracts the IgA protease precursor from the outer membrane of growing Heamophilus influenzae cells", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY AND MEETING INFO OF THE 35TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY SAN FRANCISCO, SEPT- 17-20, vol. 35, no. 0, 1995, california, usa, pages 160, XP000886820 *
See also references of WO9952545A1 *
WITTLER, M., ET AL.: "Neutralization of streptococcus sanguis IgA-1 protease by lactoferrin and transferrin", JOURNAL OF DENTAL RESEARCH AND MEETING INFO.: JOINT MEETING OF THE INTERNATIONAL ASSOCIATION FOR DENTAL RESEARCH, THE AMERICAN ASSOCIATION OF DENTAL RESEARCH AND THE CANADIAN ASSOCIATION OF DENTAL RESEARCH CHICAGO, 10-14, 1993, vol. 72, 1993, illinois, usa, pages 327, XP000886807 *

Also Published As

Publication number Publication date
JP2002508009A (ja) 2002-03-12
EP0989860A1 (en) 2000-04-05
CA2294018A1 (en) 1999-10-21
WO1999052545A1 (en) 1999-10-21
AU3554099A (en) 1999-11-01

Similar Documents

Publication Publication Date Title
IL125236A0 (en) Disinfecting compositions and processes for disinfecting surfaces
IL125237A0 (en) Disinfecting compositions and processes for disinfecting surfaces
IL133187A0 (en) Disinfecting compositions and processes for disinfecting surfaces
HK1023371A1 (en) Compositions and methods for treating viral infections
EP1052988A4 (en) USEFUL METHODS AND COMPOSITIONS FOR INACTIVATING VIRUSES
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
EP1056456A4 (en) R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
DE69918842D1 (de) Desinfektionszusammensetzungen und verfahren
HUP9901063A3 (en) Disinfecting compositions and processes for disinfecting surfaces
EP1056457A4 (en) S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
EP1083915A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING PROTEIN ANABOLISM AND DETOXICATION
EP0980202A4 (en) VIRAL INACTIVATION METHODS AND COMPOSITIONS FOR USE IN SUCH METHODS
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
EP0989860A4 (en) METHODS AND COMPOSITIONS FOR INACTIVATING INFECTIOUS AGENTS USING LACTOFERRIN AND RELATED MOLECULES
EP1135476A4 (en) BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND APPLICATIONS THEREOF
AU2003204545A1 (en) Methods and compositions for inactivating viruses
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions
EP1311709A4 (en) METHODS AND COMPOSITIONS FOR DIRECTED MOLECULAR EVOLUTION USING MODIFICATION OF THE END OF DNA
GB9828346D0 (en) Protein and compositions containing it
GB9828349D0 (en) Protein and compositions containing it
GB9828355D0 (en) Protein and compositions containing it
GB9901233D0 (en) Protein and compositions containing it
GB9901922D0 (en) Protein and compositions containing it
GB9900082D0 (en) Protein and compositions containing it
GB9901234D0 (en) Protein and compositions containing it

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FR GB IE LI LU NL SE

17P Request for examination filed

Effective date: 20000405

A4 Supplementary search report drawn up and despatched

Effective date: 20000606

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK FR GB IE LI LU NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/40 A, 7A 61K 39/02 B, 7A 61K 39/12 B, 7A 61K 39/145 B, 7C 07K 14/79 B, 7A 61P 31/04 B

17Q First examination report despatched

Effective date: 20030929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050315